A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Providence to Expand Access to In-home, Outpatient PT with Luna

Luna, the leading provider of in-home physical therapy, today announced that Providence, a not-for-profit health system serving the Western U.S., will expand access to outpatient physical therapy service through the Luna technology platform.

The Luna technology platform will match eligible Providence patients to therapists based on factors, including specialty, geography, and schedules. Luna’s broad network of local physical therapists will provide consistent, high-quality care, of the type administered in a traditional outpatient clinic, but from the comfort of a patient’s home.

“Providence is an innovative health system that is continuously finding ways to meet patients where they are,” said Prasanna Mohanty, chief operating officer for the clinical network at Providence. “We recognize that there is a growing number of physical therapy outpatients needing or wanting to remain at home, and Luna’s in-home model will enable our teams to accommodate patient needs and ensure quality care that is safe and convenient.”

The platform will allow patients and therapists to communicate with each other and discuss care needs between visits. The same therapist will treat the patient for the entirety of the treatment plan, which will ensure consistent and quality care. Between visits, patients will use the Luna platform to communicate with their physical therapists, set appointment times, and perform therapist-prescribed and monitored exercises.

Providence

“Patients demand greater flexibility in outpatient services, including the ability to choose when and where services are performed,” said Palak Shah, co-founder and head of clinical operations at Luna. “The addition of Luna’s in-home physical therapy provides relief for health systems operating at capacity and needing more access. This will allow more patients within the Providence health system to complete their treatment plan at a convenient place and time — and ensure quality and continuity of care.”

Luna will accept all insurance providers contracted with Providence, with the exception of worker’s compensation and disability.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy